Maria T. Landi, M.D., Ph.D., principal investigator at the National Cancer Institute (NCI) and National Institutes of Health (NIH) discusses a recent study that identified genetic variations that may be linked with increased melanoma risk.
David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, breaks down a common misconception that many people have about glioblastoma (GBM).
Renata Marie Vestevich, founder and developer of Essential Eyebrow Solution (EES), discusses how this topical solution may be able to help patients keep their eyebrow hair while undergoing chemotherapy.
Rebecca Arend, M.D., gynecologic oncologist at University of Alabama at Birmingham Hospital, discusses the rapidly changing field of ovarian cancer.
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.
Gary Rodin, M.D., head of the Department of Supportive Care at Princess Margaret Cancer Centre, in Toronto, Canada, discusses CALM, an intervention designed to help patients with advanced-stage cancer cope and talk about their concerns.
Yania Jansen, surgical trainee at Vrije Universiteit Brussel, in Brussels, Belgium, discusses the possibility of stopping treatment with Keytruda (pembrolizumab) for patients with melanoma.
David Reardon, M.D., clinical director at the Center for Neuro-oncology at the Dana-Farber Cancer Institute, offers advice for patients who have recently been diagnosed with glioblastoma (GBM).